Table 2.
Distribution of demographic and tumor characteristics of stages 1–3 first primary invasive breast cancer by socioeconomic status: California Cancer Registry 2000–2010*
| |
Socioeconomic status category |
||||
|---|---|---|---|---|---|
| Lowest/least affluent | Intermediate | Highest/most affluent | Total | ||
|
N (%) |
|
49,868 (27.8%) |
37,128 (20.7%) |
92,147 (51.36%) |
179,143 |
|
Year at diagnosis |
|
|
|
|
|
| 2000-2006 |
n |
31,380 |
23,844 |
59,359 |
114,583 |
| % within SES |
62.9% |
64.2% |
64.4% |
64.0% |
|
| 2007-2010 |
n |
18,488 |
13,284 |
32,788 |
64,560 |
| % within SES |
37.1% |
35.8% |
35.6% |
36.0% |
|
|
Race/ethnicity |
|
|
|
|
|
| White |
n |
25,016 |
25,283 |
70,136 |
120,435 |
| % within SES |
50.2% |
68.1% |
76.1% |
67.2% |
|
| Black |
n |
5,454 |
2,349 |
2,834 |
10,637 |
| % within SES |
10.9% |
6.3% |
3.1% |
5.9% |
|
| Hispanic |
n |
14,848 |
5,756 |
7,776 |
28,380 |
| % within SES |
29.8% |
15.5% |
8.4% |
15.8% |
|
| API |
n |
4,550 |
3,740 |
11,401 |
19,691 |
| % within SES |
9.1% |
10.1% |
12.4% |
11.0% |
|
|
Age (years) at diagnosis |
|
|
|
|
|
| <35 |
n |
1,347 |
713 |
1,628 |
3,688 |
| % within SES |
2.7% |
1.9% |
1.8% |
2.1% |
|
| 35-69 |
n |
35,557 |
25,924 |
66,589 |
128,070 |
| % within SES |
71.3% |
69.8% |
72.3% |
71.5% |
|
| 70-79 |
n |
8,414 |
6,708 |
15,388 |
30,510 |
| % within SES |
16.9% |
18.1% |
16.7% |
17.0% |
|
| 80-89 |
n |
4,022 |
3,349 |
7,565 |
14,936 |
| % within SES |
8.1% |
9.0% |
8.2% |
8.3% |
|
| 90+ |
n |
528 |
434 |
977 |
1,939 |
| % within SES |
1.1% |
1.2% |
1.1% |
1.1% |
|
|
AJCC stage |
|
|
|
|
|
| Stage 1 |
n |
21,814 |
18,066 |
47,655 |
87,535 |
| % within SES |
43.7% |
48.7% |
51.7% |
48.9% |
|
| Stage 2 |
n |
21,082 |
14,776 |
35,550 |
71,408 |
| % within SES |
42.3% |
39.8% |
38.6% |
39.9% |
|
| Stage 3 |
n |
6,972 |
4,286 |
8,942 |
20,200 |
| % within SES |
14.0% |
11.5% |
9.7% |
11.3% |
|
|
ER/PR/HER2 subtype |
|
|
|
|
|
| ER+/PR+/HER2- |
n |
18,434 |
15,088 |
40,900 |
74,422 |
| % within SES |
52.6% |
56.6% |
59.8% |
57.2% |
|
| ER+/PR+/HER2+ |
n |
3,521 |
2,519 |
6,204 |
12,244 |
| % within SES |
10.0% |
9.5% |
9.1% |
9.4% |
|
| ER+/PR-/HER2- |
n |
3,264 |
2,548 |
6,702 |
12,514 |
| % within SES |
9.3% |
9.6% |
9.8% |
9.6% |
|
| ER+/PR-/HER2+ |
n |
1,180 |
856 |
2,082 |
4,118 |
| % within SES |
3.4% |
3.2% |
3.0% |
3.2% |
|
| ER-/PR+/HER2- |
n |
285 |
212 |
527 |
1,024 |
| % within SES |
0.8% |
0.8% |
0.8% |
0.8% |
|
| ER-/PR+/HER2+ |
n |
167 |
120 |
226 |
513 |
| % within SES |
0.5% |
0.5% |
0.3% |
0.4% |
|
| ER-/PR-/HER2- |
n |
5,454 |
3,550 |
7,821 |
16,825 |
| % within SES |
15.6% |
13.3% |
11.4% |
100.0% |
|
| ER-/PR-/HER2+ |
n |
2,744 |
1,753 |
3,941 |
12.9% |
| |
% within SES |
7.8% |
6.6% |
5.8% |
8,438 |
|
Tumor grade |
n |
9,276 |
7,998 |
22,058 |
39,332 |
| Grade I |
% within SES |
19.9% |
22.9% |
25.3% |
23.3% |
| n |
18,814 |
14,625 |
37,837 |
71,276 |
|
| Grade II |
% within SES |
40.3% |
41.9% |
43.4% |
42.3% |
| n |
17,586 |
11,572 |
25,888 |
55,046 |
|
| Grade III |
% within SES |
37.7% |
33.2% |
29.7% |
32.6% |
| n |
1,001 |
698 |
1,344 |
3,043 |
|
| Grade IV | % within SES | 2.1% | 2.0% | 1.5% | 1.8% |
*Excludes cases classified as American Indian and Hispanic + Other race.